Table 6.
Top 10 co-cited research articles regarding immunotherapy for brain metastases.
| Rank | Title | First Author |
Institute (Country) | Year | Journal | IF (2023) | TLS | Citations (Ref.) |
|---|---|---|---|---|---|---|---|---|
| 1 | Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomized, open-label, phase 2 trial | Sarah B Goldberg | Yale School of Medicine (USA) |
2016 | Lancet Oncol | 51.1 | 4142 | 342 [29] |
| 2 | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Kim Margolin |
Providence Saint John’s Health Center (USA) | 2012 | Lancet Oncol | 51.1 | 4061 | 327 [40] |
| 3 | Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | Hussein A Tawbi | University of Texas, MD Anderson Cancer Center (USA) |
2018 | N Engl J Med | 158.5 | 3309 | 291 [35] |
| 4 | Improved survival with ipilimumab in patients with metastatic melanoma | F Stephen Hodi | Dana–Farber Cancer Institute (USA) | 2010 | N Engl J Med | 158.5 | 2972 | 264 [26] |
| 5 | Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomized phase 2 study | Georgina V Long | University of Sydney (Australia) | 2018 | Lancet Oncol | 51.1 | 3005 | 246 [20] |
| 6 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Hossein Borghaei | Fox Chase Cancer Center (USA) | 2015 | N Engl J Med | 158.5 | 2260 | 226 [46] |
| 7 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Martin Reck | German Center of Lung Research (Germany) |
2016 | N Engl J Med | 158.5 | 2111 | 196 [38] |
| 8 | Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment | Kiess A.P | Memorial Sloan-Kettering Cancer Center (USA) | 2015 |
Int J
Radiat Oncol Biol Phys |
7.0 | 2633 | 178 [45] |
| 9 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Larkin J. | Memorial Sloan-Kettering Cancer Center (USA) | 2015 | N Engl J Med | 158.5 | 1839 | 161 [30] |
| 10 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Brahmer Julie | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (USA) | 2015 | N Engl J Med | 158.5 | 1628 | 157 [47] |
IF, Impact Factor; TLS, Total Link Strength.